Cargando…

Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States

INTRODUCTION: Integrase strand transfer inhibitor (INSTI)‐containing antiretroviral therapy (ART) has been associated with weight gain, though there is limited information on associations between ART‐related weight gain and cardiometabolic outcomes among people living with HIV‐1 (PLWH). We, therefor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebeiro, Peter F., Emond, Bruno, Rossi, Carmine, Bookhart, Brahim K., Shah, Aditi, Caron‐Lapointe, Gabrielle, Lafeuille, Marie‐Hélène, Donga, Prina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258864/ https://www.ncbi.nlm.nih.gov/pubmed/37306118 http://dx.doi.org/10.1002/jia2.26123

Ejemplares similares

Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
por: Donga, Prina, et al.
Publicado: (2022)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Pharmacokinetic drug interactions of integrase strand transfer inhibitors
por: Lu, Chi-Hua, et al.
Publicado: (2021)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
por: Foster, Emma G., et al.
Publicado: (2022)

Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania
por: Henerico, Shimba, et al.
Publicado: (2022)

Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors
por: Chen, Yen-Wen, et al.
Publicado: (2022)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2017)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
por: Smith, Steven J., et al.
Publicado: (2021)

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
por: Richetta, Clémence, et al.
Publicado: (2022)

Pretreatment integrase strand transfer inhibitor resistance in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2023)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan
por: Tsai, Hung-Chin, et al.
Publicado: (2018)

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors
por: Foster, Emma G., et al.
Publicado: (2023)

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
por: Malet, Isabelle, et al.
Publicado: (2017)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey
por: Cecchini, Diego M., et al.
Publicado: (2019)

Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK
por: Mbisa, Jean L, et al.
Publicado: (2020)

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
por: Ni, Xiaoju, et al.
Publicado: (2012)

556. Factors Associated with Integrase Strand Transfer Inhibitor Use Between 2008 and 2015
por: O’Halloran, Jane, et al.
Publicado: (2018)

Integrase strand-transfer inhibitors for treatment of early HIV infection: A case series
por: Teira, Ramón, et al.
Publicado: (2019)

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting
por: Greenberg, Lauren, et al.
Publicado: (2022)

Impact of HIV infection and integrase strand transfer inhibitors-based treatment on the gut virome
por: Villoslada-Blanco, Pablo, et al.
Publicado: (2022)

3′-Processing and strand transfer catalysed by retroviral integrase in crystallo
por: Hare, Stephen, et al.
Publicado: (2012)

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome
por: Abram, Michael E., et al.
Publicado: (2017)

A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants
por: Sayyed, Sharif Karim, et al.
Publicado: (2023)

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1
por: Donga, Prina, et al.
Publicado: (2023)

Recent Developments in the Synthesis of HIV-1 Integrase Strand Transfer Inhibitors Incorporating Pyridine Moiety
por: Starosotnikov, Alexey M., et al.
Publicado: (2023)

No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain
por: Verburgh, Myrthe L., et al.
Publicado: (2023)

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
por: Santos, José Ramón, et al.
Publicado: (2023)

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
por: Barski, Michał S., et al.
Publicado: (2019)

334. Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens
por: Saber, Saghar, et al.
Publicado: (2019)

Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, China
por: Lan, Yun, et al.
Publicado: (2022)

Transmitted Drug Resistance Against Integrase Strand Transfer Inhibitors in Iranian HIV-Infected Naïve Patients
por: Hashempour, Ava, et al.
Publicado: (2023)

Association Between Weight Gain and the Incidence of Cardiometabolic Conditions Among People Living with HIV-1 at High Risk of Weight Gain Initiated on Antiretroviral Therapy
por: McComsey, Grace A., et al.
Publicado: (2022)

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
por: White, Kirsten L., et al.
Publicado: (2014)

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
por: Alaoui, Najwa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v3m015a6knrdtcfj7b92fkl8qr